Healthcare costs attributable to diabetes in pregnancy: A cost of illness study in Tasmania, Australia

IF 3.2 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Diabetic Medicine Pub Date : 2024-08-02 DOI:10.1111/dme.15417

Thi Thu Ngan Dinh, Barbara de Graaff, Julie A. Campbell, Matthew D. Jose, John Burgess, Timothy Saunder, Alex Kitsos, Andrew J. Palmer

{"title":"Healthcare costs attributable to diabetes in pregnancy: A cost of illness study in Tasmania, Australia","authors":"Thi Thu Ngan Dinh, Barbara de Graaff, Julie A. Campbell, Matthew D. Jose, John Burgess, Timothy Saunder, Alex Kitsos, Andrew J. Palmer","doi":"10.1111/dme.15417","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>To estimate the direct costs during the prenatal, delivery and postpartum periods in mothers with diabetes in pregnancy, compared to those without.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study used a population-based dataset from 2004 to 2017, including 57,090 people with diabetes and 114,179 people without diabetes in Tasmania, Australia. Based on diagnostic codes, delivery episodes with gestational diabetes mellitus (GDM) were identified and matched with delivery episodes without diabetes in pregnancy. A group of delivery episodes with pre-existing diabetes was identified for comparison. Hospitalisation, emergency department and pathology costs of these groups were calculated and adjusted to 2020–2021 Australian dollars.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 2774 delivery episodes with GDM, 2774 delivery episodes without diabetes and 237 delivery episodes with pre-existing diabetes identified. Across the 24-month period, the pre-existing diabetes group required the highest costs, totalling $23,536/person. This was followed by the GDM ($13,210/person), and the no diabetes group ($11,167/person). The incremental costs of GDM over the no diabetes group were $890 (95% CI 635; 1160) in the year preceding delivery; $812 (616; 1031) within the delivery period and $341 (110; 582) in the year following delivery (<i>p</i> < 0.05). Within the year preceding delivery, the incremental costs in the prenatal period were $803 (579; 1058) (<i>p</i> < 0.05). Within the year following delivery, the incremental costs in the postpartum period were $137 (55; 238) (<i>p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our results emphasised the importance of proper management of diabetes in pregnancy in the prenatal and postpartum periods and highlighted the significance of screening and preventative strategies for diabetes in pregnancy.</p>\n </section>\n </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15417","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dme.15417","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To estimate the direct costs during the prenatal, delivery and postpartum periods in mothers with diabetes in pregnancy, compared to those without.

Methods

This study used a population-based dataset from 2004 to 2017, including 57,090 people with diabetes and 114,179 people without diabetes in Tasmania, Australia. Based on diagnostic codes, delivery episodes with gestational diabetes mellitus (GDM) were identified and matched with delivery episodes without diabetes in pregnancy. A group of delivery episodes with pre-existing diabetes was identified for comparison. Hospitalisation, emergency department and pathology costs of these groups were calculated and adjusted to 2020–2021 Australian dollars.

Results

There were 2774 delivery episodes with GDM, 2774 delivery episodes without diabetes and 237 delivery episodes with pre-existing diabetes identified. Across the 24-month period, the pre-existing diabetes group required the highest costs, totalling $23,536/person. This was followed by the GDM ($13,210/person), and the no diabetes group ($11,167/person). The incremental costs of GDM over the no diabetes group were $890 (95% CI 635; 1160) in the year preceding delivery; $812 (616; 1031) within the delivery period and $341 (110; 582) in the year following delivery (p < 0.05). Within the year preceding delivery, the incremental costs in the prenatal period were $803 (579; 1058) (p < 0.05). Within the year following delivery, the incremental costs in the postpartum period were $137 (55; 238) (p < 0.05).

Conclusions

Our results emphasised the importance of proper management of diabetes in pregnancy in the prenatal and postpartum periods and highlighted the significance of screening and preventative strategies for diabetes in pregnancy.

Abstract Image

查看原文本刊更多论文

妊娠期糖尿病的医疗成本：澳大利亚塔斯马尼亚州疾病成本研究。

目的：与未患糖尿病的母亲相比，估算妊娠期糖尿病母亲在产前、分娩和产后期间的直接成本：这项研究使用了 2004 年至 2017 年的人口数据集，其中包括澳大利亚塔斯马尼亚州的 57090 名糖尿病患者和 114179 名非糖尿病患者。根据诊断代码，确定了患有妊娠期糖尿病（GDM）的分娩事件，并与没有妊娠期糖尿病的分娩事件进行了配对。同时还确定了一组患有糖尿病的分娩病例进行比较。计算了这些群体的住院、急诊和病理成本，并将其调整为 2020-2021 年澳元：结果：共发现 2,774 例患有 GDM 的分娩病例、2,774 例无糖尿病的分娩病例和 237 例患有糖尿病的分娩病例。在 24 个月期间，原有糖尿病组所需费用最高，共计 23,536 澳元/人。其次是 GDM 组（13,210 美元/人）和无糖尿病组（11,167 美元/人）。与无糖尿病组相比，GDM 在分娩前一年的增量成本为 890 美元（95% CI 635；1160），在分娩期为 812 美元（616；1031），在分娩后一年为 341 美元（110；582）（P 结论：我们的研究结果表明，在分娩前、分娩期、分娩后和分娩后一年中，适当控制血糖是非常重要的：我们的研究结果强调了在产前和产后对妊娠糖尿病进行适当管理的重要性，并强调了妊娠糖尿病筛查和预防策略的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetic Medicine 医学-内分泌学与代谢

CiteScore

7.20

自引率

5.70%

发文量

229

审稿时长

3-6 weeks

期刊介绍： Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”